Skip to Content
Merck
  • Release of PACAP-38 in episodic cluster headache patients - an exploratory study.

Release of PACAP-38 in episodic cluster headache patients - an exploratory study.

The journal of headache and pain (2016-08-01)
Bernadett Tuka, Nikoletta Szabó, Eszter Tóth, Zsigmond Tamás Kincses, Árpád Párdutz, Délia Szok, Tamás Körtési, Teréz Bagoly, Zsuzsanna Helyes, Lars Edvinsson, László Vécsei, János Tajti
ABSTRACT

Activation of the trigeminal-autonomic reflex, involving the trigeminal ganglion, the superior salivatory nucleus and the sphenopalatine ganglion (SPG) is crucial in the pathophysiology of cluster headache (CH). Since pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) is present both in the SPG and the trigeminal ganglion (TG) and its role in migraine has been described, our aim was to determine the plasma PACAP-38 levels in different phases of episodic CH (ECH). Peripheral cubital fossa blood samples were taken during the ictal and inter-bout periods of male ECH patients and from age-matched healthy controls (n = 9). Plasma PACAP-38-like immunoreactivity (LI) was measured with specific and sensitive radioimmunoassay. Significantly lower plasma PACAP-38-LI was detected in the inter-bout period of ECH patients than in healthy controls. However, PACAP-38 was significantly elevated in the plasma during CH attacks as compared to the inter-bout phase in the same subjects (n = 5). This exploratory study suggests that PACAP-38 may be released during the attacks of ECH. Further patients and long-term follow-up are necessary to reveal its function.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Pituitary adenylate cyclase activating polypeptide-38